{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&answer.groupedQuestionUIN=265417", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&answer.groupedQuestionUIN=265417", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&answer.groupedQuestionUIN=265417&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=0&answer.groupedQuestionUIN=265417", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&answer.groupedQuestionUIN=265417", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&answer.groupedQuestionUIN=265417", "items" : [{"_about" : "http://data.parliament.uk/resources/1132404", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1132404/answer", "answerText" : {"_value" : "<p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.<\/p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department\u2019s approach remains to urge Vertex to accept NHS England\u2019s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-06-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "265417"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-06-20T09:33:36.47Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-06-17", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor: Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching a large scale clinical trial of the generic version of Orkambi.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/298", "label" : {"_value" : "Biography information for Steve McCabe"}
      }
      , "tablingMemberConstituency" : {"_value" : "Birmingham, Selly Oak"}
      , "tablingMemberPrinted" : [{"_value" : "Steve McCabe"}
      ], "uin" : "265418"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}